Skip to main content
Erschienen in: American Journal of Clinical Dermatology 6/2007

01.12.2007 | Original Research Article

Comparative Study of 2% Sertaconazole Solution and Cream Formulations in Patients with Tinea Corporis, Tinea Pedis Interdigitalis, or a Corresponding Candidosis

verfasst von: Dr Claudia Borelli, Gunther Klövekorn, Thomas-Matthias Ernst, Rolf-Hasso Bödeker, Hans Christian Korting, Claudia Neumeister

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Background: Based on the results of numerous preclinical and clinical studies, sertaconazole can be considered a safe and effective drug for the treatment of fungal skin infections.
Objective: The objective of the study was to compare the efficacy of a solution containing 2% sertaconazole with the well established 2% sertaconazole cream formulation in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis.
Methods: This was a prospective, open-label, randomized, controlled, parallel-group, multicenter, noninferiority therapy study. Patients received either sertaconazole solution or cream twice daily for 28 days. The full analysis set comprised 160 patients in the solution group and 153 patients in the cream group. The primary efficacy parameter was a combination of culture test result and total clinical score. Efficacy was defined by eradication of the pathogen and reduction of the total clinical score between pretreatment and the final visit.
Results: Efficacy was documented in 90.6% of patients using the solution and 88.9% of those using the cream (full analysis set). No adverse events occurred.
Conclusion: Solution and cream formulations of 2% sertaconazole applied for 28 days were associated with comparable efficacy and safety in the treatment of fungal skin infections.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Carrillo-Munoz AJ, Torres-Rodriguez JM. In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. J Antimicrob Chemother 1995; 36: 713–6PubMedCrossRef Carrillo-Munoz AJ, Torres-Rodriguez JM. In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. J Antimicrob Chemother 1995; 36: 713–6PubMedCrossRef
2.
Zurück zum Zitat Carillo-Munoz AJ, Tur-Tur C. Comparative study of antifungal activity of serta- conazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. Chemotherapy 1997; 43: 387–92PubMedCrossRef Carillo-Munoz AJ, Tur-Tur C. Comparative study of antifungal activity of serta- conazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. Chemotherapy 1997; 43: 387–92PubMedCrossRef
3.
Zurück zum Zitat Carrillo-Munoz AJ, Tur-Tur C, Bornay-Llinares FJ, et al. Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J Chemother 1999; 11: 187–90PubMed Carrillo-Munoz AJ, Tur-Tur C, Bornay-Llinares FJ, et al. Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J Chemother 1999; 11: 187–90PubMed
4.
Zurück zum Zitat Drouhet E, Dupont B. In vitro antifungal activity of sertaconazole. Arzneimittelfor-schung 1992; 42: 705–10 Drouhet E, Dupont B. In vitro antifungal activity of sertaconazole. Arzneimittelfor-schung 1992; 42: 705–10
5.
Zurück zum Zitat Martin-Mazuelos E, Aller AI, Morilla D, et al. Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp. Chemotherapy 1996; 42: 112–7PubMedCrossRef Martin-Mazuelos E, Aller AI, Morilla D, et al. Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp. Chemotherapy 1996; 42: 112–7PubMedCrossRef
6.
Zurück zum Zitat Palacin C, Sacristan A, Ortiz JA. In vitro activity of sertaconazole. Arzneimittelfor-schung 1992; 42: 699–705 Palacin C, Sacristan A, Ortiz JA. In vitro activity of sertaconazole. Arzneimittelfor-schung 1992; 42: 699–705
7.
Zurück zum Zitat Palacin C, Sacristan A, Ortiz JA. In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. Arzneimittelforschung 1992; 42: 711–4PubMed Palacin C, Sacristan A, Ortiz JA. In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. Arzneimittelforschung 1992; 42: 711–4PubMed
8.
Zurück zum Zitat Pfaller MA, Sutton DA. Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. Diagn Microbiol Infect Dis 2006; 56: 147–52PubMedCrossRef Pfaller MA, Sutton DA. Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. Diagn Microbiol Infect Dis 2006; 56: 147–52PubMedCrossRef
9.
Zurück zum Zitat Carrillo-Muñoz AJ, Tur C, Estivill D, et al. In vitro antifungal activity of sertacon- nozazole and bifonazole against dermatophytes. J Mycol Med 1995; 5: 235–8 Carrillo-Muñoz AJ, Tur C, Estivill D, et al. In vitro antifungal activity of sertacon- nozazole and bifonazole against dermatophytes. J Mycol Med 1995; 5: 235–8
10.
Zurück zum Zitat Carrillo-Muñoz AJ, Tur C, Torres J. In vitro antifungal activity of sertaconazole, noz bifonazole, ketoconazole and miconazole against yeasts of the Candida genus.J Antimicrob Chemother 1996; 37: 815–9CrossRef Carrillo-Muñoz AJ, Tur C, Torres J. In vitro antifungal activity of sertaconazole, noz bifonazole, ketoconazole and miconazole against yeasts of the Candida genus.J Antimicrob Chemother 1996; 37: 815–9CrossRef
11.
Zurück zum Zitat Carrillo-Muñoz AJ, Bri´ S, Quind´ G, et al. Sertaconazole: in vitro antifungal noz oos activity against vaginal and other superficial yeast isolates. J Chemother 2001; 13: 555–62PubMed Carrillo-Muñoz AJ, Bri´ S, Quind´ G, et al. Sertaconazole: in vitro antifungal noz oos activity against vaginal and other superficial yeast isolates. J Chemother 2001; 13: 555–62PubMed
12.
Zurück zum Zitat Carrillo-Muñoz AJ, Fern´andez-Torres B, C´ardenes DC, et al. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility. Chemotherapy 2003; 49: 248–51PubMedCrossRef Carrillo-Muñoz AJ, Fern´andez-Torres B, C´ardenes DC, et al. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility. Chemotherapy 2003; 49: 248–51PubMedCrossRef
13.
Zurück zum Zitat Carrillo-Muñoz AJ, Fern´andez-Torres B, Guarro J. In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates. J Chemother 2003; 15: 555–7PubMed Carrillo-Muñoz AJ, Fern´andez-Torres B, Guarro J. In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates. J Chemother 2003; 15: 555–7PubMed
14.
Zurück zum Zitat Carrillo-Muñoz AJ, Guglietta J, et al. In vitro antifungal activity of sertaconazole noz compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis. Chemotherapy 2004; 50: 308–13PubMedCrossRef Carrillo-Muñoz AJ, Guglietta J, et al. In vitro antifungal activity of sertaconazole noz compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis. Chemotherapy 2004; 50: 308–13PubMedCrossRef
15.
Zurück zum Zitat Alomar C, Bassas S, Casas M, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung 1992; 42: 767–73PubMed Alomar C, Bassas S, Casas M, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung 1992; 42: 767–73PubMed
16.
Zurück zum Zitat Palacin C, Sacristan A, Ortiz JA. In vivo activity of sertaconazole in experimental candidiasis in the mouse. Drugs Exp Clin Res 1990; 16: 469–73PubMed Palacin C, Sacristan A, Ortiz JA. In vivo activity of sertaconazole in experimental candidiasis in the mouse. Drugs Exp Clin Res 1990; 16: 469–73PubMed
17.
Zurück zum Zitat Palacin C, Sacristan A, Ortiz JA. In vivo activity of sertaconazole in experimental dermatophytosis in guinea pigs. Arzneimittelforschung 1992; 42: 714–8PubMed Palacin C, Sacristan A, Ortiz JA. In vivo activity of sertaconazole in experimental dermatophytosis in guinea pigs. Arzneimittelforschung 1992; 42: 714–8PubMed
18.
Zurück zum Zitat Pedragosa R, Gonzalez B, Martin M, et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of cutaneous dermatophytosis. Arzneimittelforschung 1992; 42: 760–3PubMed Pedragosa R, Gonzalez B, Martin M, et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of cutaneous dermatophytosis. Arzneimittelforschung 1992; 42: 760–3PubMed
19.
Zurück zum Zitat Umbert P, Nasarre J, Bello A, et al. Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans. Arzneimittelforschung 1992; 42: 757–60PubMed Umbert P, Nasarre J, Bello A, et al. Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans. Arzneimittelforschung 1992; 42: 757–60PubMed
20.
Zurück zum Zitat Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, et al. Sertaconazole: updated review of a topical antifungal agent. Expert Rev Anti Infect Ther 2005; 3: 333–42PubMedCrossRef Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, et al. Sertaconazole: updated review of a topical antifungal agent. Expert Rev Anti Infect Ther 2005; 3: 333–42PubMedCrossRef
21.
Zurück zum Zitat Agut J, Palacin C, Sacristan A, et al. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittelforschung 1992; 42: 718–20PubMed Agut J, Palacin C, Sacristan A, et al. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittelforschung 1992; 42: 718–20PubMed
22.
Zurück zum Zitat Agut J, Palacin C, Salgado J, et al. Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimit- telforschung 1992; 42: 721–4 Agut J, Palacin C, Salgado J, et al. Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimit- telforschung 1992; 42: 721–4
23.
Zurück zum Zitat Guarro J, Figueras MJ, Cano J. Alterations produced by sertaconazole in the morphology and ultrastructure of Candida albicans. Mycoses 1989; 32: 283–95PubMedCrossRef Guarro J, Figueras MJ, Cano J. Alterations produced by sertaconazole in the morphology and ultrastructure of Candida albicans. Mycoses 1989; 32: 283–95PubMedCrossRef
24.
Zurück zum Zitat Agut J, Moren M, Rego M, et al. Pharmacokinetic evaluation of labelled sertacon-azole after dermal application. Arzneimittelforschung 1992; 42: 748–51PubMed Agut J, Moren M, Rego M, et al. Pharmacokinetic evaluation of labelled sertacon-azole after dermal application. Arzneimittelforschung 1992; 42: 748–51PubMed
25.
Zurück zum Zitat ICH harmonised tripartite guideline. Statistical principles for clinical trials: E9. 1998 Feb 5 [online]. Available from URL: http://www.ich.org/ [Accessed 2008 Nov 7] ICH harmonised tripartite guideline. Statistical principles for clinical trials: E9. 1998 Feb 5 [online]. Available from URL: http://​www.​ich.​org/​ [Accessed 2008 Nov 7]
26.
Zurück zum Zitat Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 1996; 34 (2 Pt 1): 282–6CrossRef Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 1996; 34 (2 Pt 1): 282–6CrossRef
27.
Zurück zum Zitat Schäfer H, Zesch A, Stüttgen G. Skin permeability. Berlin: Springer, 1982 Schäfer H, Zesch A, Stüttgen G. Skin permeability. Berlin: Springer, 1982
28.
Zurück zum Zitat Surber C, Smith EW. The mystical effects of dermatological vehicles. Dermatology 2005; 210: 157–68PubMedCrossRef Surber C, Smith EW. The mystical effects of dermatological vehicles. Dermatology 2005; 210: 157–68PubMedCrossRef
29.
Zurück zum Zitat Korting HC, Rychlik R, Pfeil B. Treatment of interdigital tinea pedis [in German]. Dtsch Med Wochenschr 2003; 128: 1819–24PubMedCrossRef Korting HC, Rychlik R, Pfeil B. Treatment of interdigital tinea pedis [in German]. Dtsch Med Wochenschr 2003; 128: 1819–24PubMedCrossRef
30.
Zurück zum Zitat Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36–9PubMedCrossRef Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36–9PubMedCrossRef
31.
Zurück zum Zitat Susilo R, Korting HC, Strauss UP, et al. Dermatomycoses of the glabrous skin: a double-blind, randomised, comparative trial of sertaconazole 2% cream once daily versus vehicle. Clin Drug Invest 2003; 23: 387–94CrossRef Susilo R, Korting HC, Strauss UP, et al. Dermatomycoses of the glabrous skin: a double-blind, randomised, comparative trial of sertaconazole 2% cream once daily versus vehicle. Clin Drug Invest 2003; 23: 387–94CrossRef
32.
Zurück zum Zitat Gentle JC, Jones GR, Roberts DT. Efficacy of miconazole in the topical treatment of tinea pedis in sportsmen. Br J Dermatol 1975; 93: 79–84CrossRef Gentle JC, Jones GR, Roberts DT. Efficacy of miconazole in the topical treatment of tinea pedis in sportsmen. Br J Dermatol 1975; 93: 79–84CrossRef
33.
Zurück zum Zitat Kieser M, Friede T. Planning and analysis of three-arm non-inferiority trials with binary endpoints. Stat Med 2007; 26: 253–73PubMedCrossRef Kieser M, Friede T. Planning and analysis of three-arm non-inferiority trials with binary endpoints. Stat Med 2007; 26: 253–73PubMedCrossRef
Metadaten
Titel
Comparative Study of 2% Sertaconazole Solution and Cream Formulations in Patients with Tinea Corporis, Tinea Pedis Interdigitalis, or a Corresponding Candidosis
verfasst von
Dr Claudia Borelli
Gunther Klövekorn
Thomas-Matthias Ernst
Rolf-Hasso Bödeker
Hans Christian Korting
Claudia Neumeister
Publikationsdatum
01.12.2007
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 6/2007
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200708060-00007

Weitere Artikel der Ausgabe 6/2007

American Journal of Clinical Dermatology 6/2007 Zur Ausgabe

Review Article

Eyebrow Loss

Review Article

Palmar Erythema

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.